PepGen Inc. (PEPG)
NASDAQ: PEPG · IEX Real-Time Price · USD
13.49
+0.33 (2.51%)
At close: May 20, 2024, 4:00 PM
12.99
-0.50 (-3.71%)
After-hours: May 20, 2024, 6:13 PM EDT

Company Description

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.

Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.

PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

PepGen Inc.
PepGen logo
Country United States
Founded 2018
IPO Date May 6, 2022
Industry Biotechnology
Sector Healthcare
Employees 65
CEO Dr. James G. McArthur Ph.D.

Contact Details

Address:
1 Marina Park Drive, Suite 900
Boston, Massachusetts 02210
United States
Phone 703-456-8000
Website pepgen.com

Stock Details

Ticker Symbol PEPG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $12.00
CIK Code 0001835597
CUSIP Number 713317105
ISIN Number US7133171055
SIC Code 2834

Key Executives

Name Position
Dr. James G. McArthur Ph.D. President, Chief Executive Officer, Treasurer, Secretary and Director
Noel P. Donnelly M.B.A. Chief Financial Officer
Niels Svenstrup Ph.D. Senior Vice President of Chemistry, Manufacturing and Control
Dr. Michael Gait Ph.D. Founder and Scientific Advisory Board Member
Mary Beth DeLena General Counsel and Secretary
Dr. Michelle L. Mellion M.D. Senior Vice President and Head of Clinical Development
Emiko Bryant Chief of Staff
Kyle Breidenstine Vice President of Finance and Controller

Latest SEC Filings

Date Type Title
May 17, 2024 144 Filing
May 14, 2024 10-Q Quarterly Report
May 14, 2024 8-K Current Report
May 1, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 16, 2024 PRE 14A Other preliminary proxy statements
Apr 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 29, 2024 10-K/A [Amend] Annual report
Mar 15, 2024 8-K Current Report